Reaction

Retinal Vein Occlusion reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,814 reports · 46 co-occurring drugs

As of the last recalculation, Retinal Vein Occlusion appears in 2,814 FAERS reports alongside 46 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 59.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranibizumab	200	59.9	60.4
Faricimab	46	42.7	42.9
Aflibercept	109	26.8	26.9
Raloxifene Hydrochloride	45	23.2	23.2
Dorzolamide Hydrochloride And Timolol Maleate	15	14.1	14.1
Baricitinib	14	10.8	10.8
Brinzolamide	12	10.3	10.3
Timolol Maleate	11	8.2	8.2
Sildenafil Powder,	34	7.1	7.1
Brimonidine Tartrate	16	6.7	6.7
Sildenafil Citrate	110	6.6	6.6
Trametinib	21	6.5	6.5
Dabrafenib	18	6.4	6.4
Sildenafil	49	6.3	6.4
Bevacizumab	100	6.2	6.2
Drospirenone And Ethinyl Estradiol	36	6.1	6.1
Testosterone	18	5.7	5.7
Bimatoprost	22	5.7	5.7
Vemurafenib	9	5.6	5.6
Atovaquone	6	5.5	5.5
Dutasteride	6	5.5	5.5
Phenytoin	15	5.3	5.3
Tofacitinib Citrate	9	5.1	5.1
Prednisolone Acetate	7	5.0	5.0
Sorafenib	14	5.0	5.0
Imatinib	11	4.6	4.6
Estradiol Gel 0.1%	28	4.6	4.6
Estradiol Transdermal	28	4.6	4.6
Estradiol	51	4.4	4.4
Latanoprost	26	3.8	3.8
Romosozumab-Aqqg	7	3.8	3.8
Axitinib	10	3.8	3.8
Abemaciclib	9	3.3	3.3
Upadacitinib	35	3.2	3.2
Fingolimod Hcl	37	3.2	3.2
Carfilzomib	12	3.1	3.1
Eltrombopag Olamine	9	2.9	2.9
Azacitidine For	7	2.9	2.9
Azacitidine	11	2.7	2.7
Lenvatinib	12	2.7	2.7
Ribavirin	22	2.5	2.5
Vismodegib	3	2.5	2.5
Encorafenib	3	2.2	2.2
Conjugated Estrogens And Medroxyprogesterone Acetate	7	2.2	2.2
Galcanezumab-Gnlm	5	1.2	1.2
Etonogestrel	7	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.